Announcements
- Traws Pharma’s ICAR Poster Highlights Potency of COVID-19 Candidate
- Traws Pharma Reports First Quarter 2024 Financial Results and Provides Business Update
- Traws Pharma Completes First Cohort Dosed in Phase 1 Trial for COVID Therapy
- Traws Pharma Announces New Employee Inducement Grants
- Onconova Therapeutics, Inc. and Trawsfynydd Therapeutics, Inc. Announce Business Combination to Form Traws Pharma, Inc, a Best-in-Class Virology and Oncology Company
- Onconova Therapeutics’ Rigosertib Poster Selected for AACR 2024
- Onconova Therapeutics’ Narazaciclib ASH Poster Highlights Activity in Treatment Resistant Mantle Cell Lymphoma
- Onconova Therapeutics’ Preclinical Narazaciclib Data at SABCS Highlights Differentiated Anti-Tumor Activity v. Other CDK4/6i’s
- Onconova Therapeutics to Present at NobleCon19, Noble Capital Markets’ Nineteenth Annual Emerging Growth Equity Conference
- Onconova Therapeutics Reports Corporate Update and Announces Third Quarter 2023 Financial Results
More ▼
Key statistics
On Friday, Traws Pharma Inc (0T2:DUS) closed at 0.535, 4.90% above its 52-week low of 0.51, set on Jun 06, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.535 |
---|---|
High | 0.55 |
Low | 0.535 |
Bid | 0.565 |
Offer | 0.61 |
Previous close | 0.545 |
Average volume | 0.00 |
---|---|
Shares outstanding | 25.30m |
Free float | 21.60m |
P/E (TTM) | -- |
Market cap | 15.04m USD |
EPS (TTM) | -0.8641 USD |
Data delayed at least 15 minutes, as of Jun 07 2024 18:30 BST.
More ▼